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Abstract 
 
  
A transgenic animal is an animal into whose genome foreign DNA has been transferred 
for the purpose of studying and manipulating that DNA. The use of such animals in research, 
medical fields, and industry has many possibilities; however, there remain many ethical and legal 
questions regarding their creation and usage. The purpose of this IQP was to explore the methods 
and technological advances involved in the creation of transgenic animals, and investigate their 
impact on society via the legal and ethical ramifications of their development. Upon examining 
current information regarding transgenic animals, it can be concluded that with the proper 
precautions they can provide enormous benefits for society. 
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Executive Summary 
 
 
Animals have been used in the laboratory for research for many years; however, recently 
a new technological development has significantly increased their usefulness and opened many 
doors in medical and research fields. This development is the creation of transgenic technology. 
Transgenic animals are animals with modified genomes containing foreign DNA for the purpose 
of studying and understanding that DNA. The animals have great potential for providing insights 
into many of humanity’s illnesses and disorders, as well as providing answers for other questions 
and problems in the modern world. 
Before scientists knew about the benefits of studying DNA and ways to manipulate it, 
farmers utilized this technology by using selective breeding to create more lucrative animals.  
Many advances have been made in the study of genetic technology.  Ever since the first 
transgenic mouse was created in 1980, scientists have been creating new methods for generating 
these very useful animals.  The current methods used for making transgenic animals are DNA 
microinjection into oocyte pronucleus, DNA microinjection into ES cells, DNA homologous 
recombination with ES cells, DNA viral delivery into ES cells, and DNA chemical delivery into 
ES cells.   
Transgenic animals today are varied in species and in purpose. Some animals are models 
for diseases such as Alzheimers, cancer, AIDS, and even Parkinson’s disease. Many disease 
models are mice, although fruit flies and even small fish have been created to help elucidate the 
nature of such ailments. Using transgenic animals to study disease has many advantages; it is 
more feasible than studying the disease in humans, the animals reproduce rapidly, especially 
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mice and other rodents, and mice in particular are cheap and readily available. Transgenic 
disease models provide good examples in the study of causes and treatments of disease. 
Other types of transgenic animals include transpharmers, which are goats, pigs, cows, and 
even some rodents, that contain human proteins in their milk. Transpharmers have the potential 
to provide relatively inexpensive and accessible drugs even to people in undeveloped countries. 
A source of much-needed organs, cells, and tissues could be Xenotransplanters, which are 
animals that are designed to contain human tissue or at least tissue that will not be rejected by the 
human body. Another type of transgenic animal is animals used for food sources, which are 
typically engineered with growth hormone genes and other genes to be larger, leaner, and more 
efficient. The last category of transgenic animals includes scientific models, which contain genes 
that help clarify biological mechanisms often involved in development. 
Using animals in research and study is nearly unavoidable if we are to save and improve 
human lives, but changing the very composition of an animal to suit the needs of human beings 
causes an ethical debate. People question the right of scientists to “play god” by altering animals. 
Many also wonder if the animals suffer from the changes brought on by the foreign DNA. 
However, most of the successful transgenic animals around today do not appear to suffer more 
than is acceptable, and it appears that the animals provide enough benefit to society to offer 
evidence that they should continue to be in use. 
 Transgenic animals have also become a controversial topic in the courts.  Along with the 
question of should transgenic animals be created comes the question should they be patented?  
The landmark case that started the problem was when Dupont and a few Harvard scientists tried 
to patent their mouse that was genetically altered to contract cancer, otherwise known as 
oncomouse.  This legal dilemma was not just restricted to the United States; it had effects in 
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Europe and Canada.  The United States and Europe both eventually granted the patent although it 
took one appeal in Europe for the patent to be passed.  Canada saw things a little differently and 
denied the patent.  Animal rights groups still believe that animals should not be patented because 
they are life forms that should be treated with respect. 
Overall, the authors of this IQP believe that the benefits of using transgenic animals 
outweigh the problems. They provide enormous opportunities for study, and have the potential to 
lead to many important medical discoveries that may save lives. Although we agree that their use 
raises ethical concerns, with careful laws and regulation, as well as improved procedures for 
creation and handling, suffering can be kept minimal while still producing good results. The 
profitable products and discoveries brought about by the different types of animals are well 
worth the effort, and hopefully transgenic animals will bring about many answers to problems in 
today’s society. 
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Project Objective 
 
 
 
The purpose of this IQP was to explore the field of transgenic animal research, which is a 
recently developed and rapidly growing field with many applications in research and medicine. 
A part of the IQP focuses on defining and classifying current transgenic animals and their uses. 
Emphasis was also placed upon examining the techniques used to produce transgenic animals as 
well as the societal impact of their creation, including the legal and ethical questions they present. 
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Chapter 1:  Transgenic Animal Description and Construction 
 
 
 A transgenic animal is an animal whose genome has been altered by the inclusion of 
foreign genetic material.  An organism’s genome is the set of genes that ensure the transmission 
of hereditary material.  The foreign genetic material is introduced to the organism through 
recombinant DNA technology.  Recombinant DNA technology is a group of techniques used to 
cut apart and splice together pieces of DNA.  The purpose of adding a new gene to an organism’s 
genome is to have the organism produce a protein or set of proteins that it did not produce before 
the gene was added.  This has many practical industrial and research uses which will be 
presented in Chapter 2. 
 
Transgenic History 
 Before the advent of molecular genetics, the only practical way to study mammalian 
genetic regulation and function was to observe certain traits and to utilize spontaneous mutants.  
The group of people who actually used this technique the most was farmers because they would 
selectively breed their animals to make them more marketable.  For example a farmer might 
breed a male cow that is very large with a female that produces the most milk in hopes that the 
baby cow will grow up to be large to yield high amounts of meat, or as a female produce the 
most milk.  
  In the 1970s the first chimeric mouse was produced (Transgenic Animal Science:  
Principles and Methods, 1991).  A chimera is an animal that consists of two or more tissues that 
have different genetic compositions produced by genetic engineering.  This means that some of 
the cells are transgenic and some of the cells in the organism are not.  The chimeric mouse was 
 9 
constructed by introducing cells from one strain of mouse into the embryos of another strain of 
mouse by microinjection into the blastocyst stage embryo which is a day-5 embryo that contains 
anywhere from 100-150 cells.  The embryo was then implanted into a surrogate mother, and 
allowed to grow into a chimeric adult mouse that exhibited characteristics of each strain of 
mouse.  
 The next step in the development of transgenic technology was use of retroviruses to 
deliver foreign DNA into embryos.  This was a successful experiment in that the viral genetic 
information was transferred into the mouse genome (Gordon et al, 1980), however, the retrovirus 
caused a high degree of mosaicism, which is a condition where only some of the cells in the 
tissues of an organism receive the genetic change while the other cells are the original genetic 
material without the desired addition.  The other problem with this technology was the viral 
sequences may interfere with transgene expression. 
 After the study of the retroviral delivery technique, scientists focused their attention to 
creating transgenic animals that would actually produce the transgene protein.  In 1980-1981, the 
first transgenic animal was produced by Gordon and Ruddle (Pinkert, 1999).  Gordon and 
Ruddle also coined the term “transgenic” because they were looking for a word to describe the 
mice that were carrying new genes (Gordon and Ruddle, 1981; Pinkert, 1999).  The production 
of these transgenic mice led to the discovery of new techniques for creating these transgenic 
animals.    
 Another advance in transgenic technology came when embryonic stem cell-mediated 
techniques were perfected.  Embryonic stem (ES) cells are cells that are derived from the inner 
mass cells of the embryo at the blastocyst stage.  ES cells are very useful because they are 
pluripotent, meaning they have the ability to grow into any of the 200 cell types in the body.   
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 Currently, many techniques are used to create these useful animals, and the five most 
popular techniques will be described in further detail for the remainder of this chapter.  The 
techniques are DNA microinjection into the oocyte pronucleus, DNA microinjection into ES 
cells, DNA homologous recombination with ES cells, DNA viral delivery into ES cells, and 
DNA chemical delivery into ES cells. 
    
DNA Microinjection into Oocyte Pronucleus 
 Pronuclear microinjection is the most popular and most successful technique used to 
create transgenic animals.  In this method, scientists first isolate the piece or pieces of DNA they 
want and clone it into a vector such as a plasmid.  Then they harvest newly fertilized eggs before 
the pronuclei fuse.  A pronucleus is the nucleus of the sperm cell (male) or egg cell (female) 
before they join to become the fertilized zygote.  Next the piece of DNA that has been isolated is 
placed in a syringe and injected into the pronucleus of the sperm cell as seen in Figure 1. 
 
 
Figure 1: Injection of DNA into a one cell 
embryo that is being held in place by a mild 
suction pipette (left of diagram).  The tip of 
the needle is on its way to piercing the 
plasma membrane and injecting the DNA 
into the sperm cell pronucleus which can be 
seen as the larger circular indent on the 
bottom of the cell.  (Chen, 1999) 
 
 
 
 
 
 When the pronuclei have fused to become the nucleus of the new zygote, the cells are 
allowed to divide to form two embryonic cells.  Then the embryo is transferred into the uterus of 
a pseudopregnant mouse, which is a female mouse that has been mated with a vasectomized 
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male mouse.  The reason for mating the female with a vasectomized male mouse, a mouse that 
has had its vans deferens removed to sterilize the mouse, is to stimulate the hormones in the body 
to make her uterus receptive to the embryo that will be transplanted in it.  The inclusion of the 
transgene DNA by microinjection is a random process, so not all of the pups born will have this 
gene expressed.  This could happen if the gene inserts itself in an area of DNA that is not 
normally expressed, so a sample of the pups tissue from the tail will be taken and the DNA 
examined to see if the transgene was included.  Pronuclear microinjection continues to be the 
most popular method for making transgenic animals due to the fact that it can be used for many 
different species.   
 
DNA Microinjection into ES Cells 
 The second method for creating transgenic animals employs the microinjection of DNA 
into embryonic stem (ES) cells.  Pronuclear fertilized eggs are collected from the oviduct of a 
donor female.  They are associated with sticky follicular cumulus cells that must be removed 
using the enzyme hyaluronidase.  Then, once the cells are free from the follicular cumulus cells, 
the embryos are transferred into a pool of medium on a petri dish and covered with a sterile, 
autoclaved mineral oil to avoid contamination by microorganisms and debris, and to prevent 
evaporation.   
 The preparation of the DNA transgene is also very important because any contamination 
will ruin the experiment.  The DNA fragment that is to be used is purified to rid it of any 
contaminants or traces of agarose, and to make sure that the DNA is intact and not ruined in any 
way.  After this is performed, the transgene is cloned in a plasmid, and then isolated from the 
plasmid by restriction enzymes.  To make sure that the restriction enzymes have cut the DNA 
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where desired, gel electrophoresis is utilized.   When the transgene is prepared, it is 
microinjected into the ES cells.  The cells are then allowed to grow to the blastocyst stage, and 
then they are transplanted into the uterus of the pseudopregnant mother.  Figure 2 shows a 
pictorial form of what is happening in both methods discussed so far. 
 
 
 
 
 
Figure 2: Diagram depicting the 
injection of DNA into the 
pronucleus and into embryonic 
stem cells which are two methods 
for creating transgenic animals. 
(Transgenic Animals, 2003) 
 
 
 
 
 
DNA Homologous Recombination with ES Cells 
 The third method for creating transgenic animals involves DNA homologous 
recombination with ES cells.  In this method the DNA sequence of the transgene is attached to a 
known portion of the host’s chromosome.  Then during meiosis, which is the process in which 
gametes (i.e. ovum and sperm) are created, each chromosome pairs with the other chromosome 
that is homologous to it creating a homologous pair.  While these chromosomes are paired, they 
cross over each other, and in turn, exchange the pieces of chromosomes.  This will create a 
portion of the chromosome that has the transgene and the other portion would be an unknown 
part of the host’s genome.  The other chromosome would contain the known part of the 
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chromosome that was originally attached to the transgene, and the part of the other chromosome 
that was unknown.   
 
Figure 3: Diagram showing the concept of 
homologous recombination.  The transgene is 
denoted in blue and on either side of it is the 
known host DNA.  The crossover points are 
the large X’s and the final product of the 
recombination can be seen as the last line 
including the transgene and the other yellow 
portions which represent the host’s DNA 
(Genoway, 2003). 
 
 
 
 
The process of homologous recombination occurs when the DNA chromosome construct 
is introduced to the embryonic stem cell pronucleus.  The resulting pronucleus with the 
recombined DNA is allowed to grow to the blastocyst stage.  After it reaches the blastocyst stage, 
it is implanted into the surrogate mother.  Homologous recombination allows experimenters to 
target a mutation in a specific location of the genome (Bronson, 1994). 
 
 
 
DNA Viral Delivery into ES Cells 
 The fourth method used for production of transgenic animals is retroviral delivery of 
DNA into embryonic stem cells.  Retroviruses are viruses that have ribonucleic acid (RNA) as 
their genetic material instead of deoxyribonucleic acid (DNA).  They also have an enzyme called 
reverse-transcriptase which can make DNA from RNA.  These viruses are altered so that they 
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will not destroy the host cells that they are to invade.  The experimenters then place the transgene 
inside of the retrovirus.  Next they microinject the virus into the embryo and let it infect the 
embryo with the transgene.  After that the embryo is allowed to grow to the blastocyst stage and 
is transplanted into the surrogate mother 
 This method can be problematic though because it creates animals that are mosaics (the 
virus does not infect all the cells), and the viral sequences necessary for the virus to do its job of 
infecting the cells may interfere with the expression of the transgene.  Also the size of the 
transgene sequence that can be added to the virus is limited.  Also the animals that are created 
will only transmit the gene to their offspring if the germ cells get a copy of the transgene, and 
with retrovirus-mediated transgenesis there is no guarantee that a germ line cell will receive the 
transgene. 
 
DNA Chemical Delivery into ES Cells 
 The final method that will be discussed is using chemicals to deliver DNA into an 
embryonic stem cell.  This method is highly similar to retroviral delivery of DNA, however, the 
carrier of the DNA into the cell is not a retrovirus, but a chemical such as calcium phosphate. 
 
 
Screening of Transgenic Animals 
 Several assays are used to test to see if the animals that were just created actually have 
the transgene and are, in fact, transgenic.  Perhaps the most widely used assay is the “Southern 
blot” assay.  This technique involves digestion of the DNA with an appropriate restriction 
enzyme, and then analyzing the digested DNA on an agarose gel.  Electric current is run through 
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the gel, and the fragments of DNA migrate from the negative pole to the positive pole.  The 
fragments move and stop in the gel according to size.  The bigger fragments are stopped at the 
top of the gel while the smaller ones move faster through the sieve and move closer to the 
positive pole.  Once that is done, the DNA is denatured by using either a strong base such as 
sodium hydroxide or a strong acid such as hydrochloric acid.  The DNA is then blotted onto a 
membrane that retains the pattern that is left by the gel electrophoresis, and a probe is hybridized 
to the DNA gene of choice, in this instance it would be the transgene.  If the animal’s cells have 
the transgene, then the blotted membrane will pick up the probe and illuminate the gene.  A 
pictorial view of southern blotting can be seen in Figure 4. 
 
    Figure 4: Diagram that shows the basic steps of a  
southern blot. (Khalsa, 2000)  
 
 Another type of assay that researchers use to determine if they have created a transgenic 
animal is the western blot.  This technique is used to detect if the animal is actually producing 
the transgenic protein.  First a gel electrophoresis is performed on a SDS-polyacrylamide gel 
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(Khalsa, 2000).  As with the DNA gel electrophoresis, the smaller the protein, the further it 
travels on the gel toward the positive pole.  After the gel is finished running, the protein is 
blotted to a nitrocellulose membrane and incubated with a primary antibody which sticks to the 
protein of interest, in this case the transgenic protein, and forms an antibody-protein complex.  
The antibody is then visualized by hybridizing to a secondary antibody that forms a color.  If the 
transgenic protein is there, a dark band can be seen on the film. A western blot is shown in 
Figure-5. 
 
 
 
 
 
Figure 5: Western immunoblotting and 
deglycosylation of organ of Corti proteins.  The 
darker bands indicate the proteins that were 
present in the sample due to the antibody sticking 
to the protein on the gel (Kansas State University, 
2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The last type of assay that we wish to discuss is an ELISA or an Enzyme Linked 
Immunoabsorbent Assay.  This technique is also used to identify the presence of transgenic 
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proteins rather than western blotting.  An ELISA measures the amount of antibodies or proteins 
in urine, blood, and animal serums.  An ELISA is performed using a plastic tray that has wells.  
In the first type, the wells are coated with a specific antigen that will capture antibodies from the 
blood etc to show if the animal is producing antibodies for the transgene.  If the antigen is 
specific to the antibodies in the sample then they will attach and enzymes in the well will react to 
produce a color.  If there is no color in the well, then there is no transgenic protein available in 
the sample.  In the second type of ELISA, specific antibodies are used to coat the wells, and they 
react with the transgenic protein when present in the blood, etc.  Figure-6 shows an ELISA. 
    
 
 
Figure 6: An example of an 
ELISA.  The wells with the 
more yellow coloring have 
more antibodies present in the 
sample than the wells that have 
no color (MacLean, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mice were the first animals to be transgenically altered, but since then, scientists have 
used different species for transgenesis.  Also these transgenic animals have many diverse uses 
which will be explained in the next chapter. 
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Chapter 2: Transgenic Animal Classification and Examples 
 
Today’s transgenic animals have many uses and purposes, and they represent a variety of 
species. Modern transgenic animals have many uses in the laboratory but are also showing 
promise in medical and agricultural fields. From animals designed to help understand, cure, and 
treat disease, to animals created to be superior producers of milk or hormones, these animals can 
have a great impact on human life in the coming years. Examples and classification of the most 
useful and common transgenic animals in today’s society will be explored in this chapter. 
 
Transgenic Disease Models  
 When the subject of transgenic animals is mentioned, laboratory mice often come to mind. 
For many years, the fast-breeding, manageable, and well-understood mouse has had a place in 
the lab. However, the average mouse has only a limited potential toward studying human 
afflictions; transgenic mice, on the other hand, can be created to specifically focus on an 
important aspect of disease. Today, mice have been created as a variety of disease models in 
order to further knowledge about many of humanities maladies. Transgenic mice that show 
symptoms of AIDS, the pathology of Alzheimer’s disease, or cancerous tumors are an 
indispensable resource for laboratories studying illness. 
 One of the first transgenic mice to catch the attention of the public was Alzheimer’s 
Mouse when it was announced in Nature in 1995 (Games, Adams et al, 1995).  Prior to then, 
there had not been a successful attempt to produce a mouse that showed the pathology of 
Alzheimer’s that was necessary for showing whether amyloid (the protein comprising senile 
plaques) production could initiate the disease. However, this new mouse finally showed the 
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potential of developing Alzheimer’s to an extent which other mouse models of the disease had 
not. “Animals transgenic for APP have previously failed to show extensive AD-type 
neuropathology, but we now report the production of transgenic mice that express high levels of 
mutant APP… and which progressively develop many of the hallmarks of AD” (Games, Adams, 
et al, 1995).  This model was subsequently used to make the first Alzheimer’s vaccine that 
cleared the senile plaques from the mouse brain and restored function (Schenk et al, 1999).  In 
2000, a similar mouse model began to be used in a study for a vaccine against Alzheimer’s; 
although the results have not yet been concluded, the data looks good and could possibly lead to 
a successful vaccine (Jones 2000).  Elan Pharmaceuticals is currently in phase II human clinical 
trials with a second generation vaccine developed using the original mouse model, but this data 
is not yet available.  Since the mouse was developed, many mice have been produced through 
transgenic means to improve upon the original Alzheimer’s Mouse or to focus on specific 
aspects of the illness; however, the first mouse was a big step necessary for the understanding of 
the disease. 
 Another important model for disease is the Oncomouse, which is also known as Harvard 
Mouse. Designed in the mid-1980’s by scientists at Harvard and its partner company DuPont, 
Oncomouse is specifically engineered to develop cancer, and many of the mice have tumors 
before they reach a year of age. In the study, all the female mice developed mammary tumors by 
their third pregnancies (Stewart, 1984). The mice carry an activated oncogene which is 
responsible for its high susceptibility to cancer. The mouse received the first animal patent in 
1988, and was labeled “Product of the Year” due to its suitability and potential for research. The 
Oncomouse has been integral in studies for cancer drugs and treatment, and it provides scientists 
 20 
with many opportunities to discover the environmental and physiological sources for developing 
cancer. 
 Another notable mouse model is the AIDS mouse. Originally, the only animal available 
to scientists for AIDS and HIV research was the chimpanzee, but since primates are expensive 
and chimpanzees are rare, and the chimps also do not progress from HIV to AIDS stage of 
infection, the research was very limited. Previous to the transgenic AIDS mouse, mice had not 
been suitable toward studying vaccines and treatment for the AIDS virus, since mice cannot be 
infected by HIV. The cells of mice lack at least one of the factors that allow HIV virus 
replication; while this lead to some discoveries toward the life cycle of HIV and how it survives 
in the cell, this was not altogether useful toward studying disease treatments. Mouse cells had 
even been modified to express the receptor, co-receptor, and the three human proteins that were 
necessary for the vaccine to attack and replicate successfully in a cell; nonetheless, the cells were 
still unable to grow HIV. 
However, in 2001, scientists at Baylor College of Medicine injected genetically modified 
HIV into mice and succeeded in retrieving HIV from mouse cells (Baylor, 2001), and they were 
also successful in growing HIV in mouse cells containing one human chromosome. Finally, one 
female mouse was created which carried active copies of the AIDS provirus, and upon breeding 
with a normal male mouse one third the offspring showed symptoms of AIDS (Bunce and Hunt, 
2004). The mouse demonstrated the pathology and the immunological failure that is expected in 
AIDS victims; this mouse model has great potential in facilitating research for AIDS because it 
allows scientists to study the virus and possible treatments without using human patients. 
 Many other mouse models for disease have been engineered. For example, mice have 
been created to develop Parkinson’s disease, cardiovascular problems, obesity, hormonal 
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deficiencies, anemia, and many other afflictions. Transgenic mice exist to study neurological 
disorders; mice have been created with dysfunctional vision, altered ability to sense pain and 
heat, modified chemical receptors in the brain and nervous systems, and some even mimic the 
pathology of stroke victims. Transgenic mice are used to study diabetes and pancreatic failure. 
In addition to mice, Parkinson’s Fly has been developed to further research in 
Parkinson’s disease. The fly demonstrates, “normal and mutant forms of α-synuclein … and 
produce(s) adult-onset loss of dopaminergic neurons, filamentous intraneuronal inclusions 
containing α-synuclein, and locomotor dysfunction. (The) Drosophila model thus recapitulates 
the essential features of the human disorder, and makes possible a powerful genetic approach to 
Parkinson's disease” (Feany and Bender, 2000).  Drosophila (the fruit fly), Danio rerio (the 
zebrafish) and C. elegans (a worm) have all been used in genetic studies and have lead to some 
transgenic models as well. Without these disease models, scientists would be much more limited 
in their options for studying disease; it is not advisable or socially acceptable to study human 
patients the same way as it is to study animal models. Many advances in understanding common 
disorders could not have been made without the use of transgenic technology. 
 
Transpharmers 
 The second major class of transgenic animal is the Transpharmer.  Transpharmers are 
agricultural animals that have been modified with transgenic technology to be more productive 
or to exhibit a desired trait. Some have been made to be larger and leaner than their natural 
counterparts, and some transpharmer animals create hormones in their milk. The large amounts 
of proteins produced by the animals are also advantageous because of the post-translational 
modifications to the proteins, such as cleavage and glycosylation,  that their cells do 
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automatically; these processes are time consuming and more difficult to do in a laboratory 
situation with any efficiency (Houdebine 1997). Many of the supplements that transpharmer 
animals create in their milk provide a cheaper and more accessible way for patients in need to get 
their medication. 
 One of the most notable transpharmer sheep was one of the first, created in 1997 to 
produce human clotting factor IX (FIX) in its milk. “FIX plays an essential role in blood 
coagulation, and its deficiency results in hemophilia B. This disease is currently treated with FIX 
derived mainly from human plasma. Recombinant FIX produced in milk would provide an 
alternative source at lower cost, and free of the potential infectious risks associated with products 
derived from human blood” (Schnieke, et al. 1997). After initially testing their transgene 
construct in mice and finding it to be successful, sheep were produced that carried the gene. This 
was significant because it was one of the first animals, other than mice, produced using cell-
mediated transgenesis, and although problems remained to be solved, the project was deemed a 
success. 
In another example, a transpharmer sheep that produces the human protein alpha-1-
antitrypsin, or AAT, provides extracted protein from its milk that is vital to patients with a 
protein deficiency that leads to dangerous lung problems. PPL Therapeutics of Edinburgh, 
Scotland, the lead company involved in the development of Dolly the cloned sheep, created the 
animal with the hopes of producing a cheaper and more efficient way to get the hormone to 
patients than through the current, expensive method of transfusion. The protein is normally 
limited in supply and costs each patient up to $80,000 each year; with the transpharmer sheep 
producing the hormone, the price is predicted to be more reasonable (White 1999).  Some 
estimates predict that the cost of some medications could be lowered from $1000 a gram to only 
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$2 per gram using transgenic technology.  It is also important to note that the production of 
foreign hormones and proteins in their milk does not appear to harm the transpharmer animal. 
One of the most notable transpharmer animals is Herman the Bull.  Herman has been 
engineered to carry a gene for lactoferrin. It is hoped that his female offspring will produce the 
protein in their milk and thus alleviate the need for human babies to drink formula or mother’s 
milk unnaturally low in this protein. Without the lactoferrin, human babies cannot survive on 
cow’s milk. Herman the Bull fathered eight calves in 1994 (Biotech Notes 1994). With the 
success of his offspring, cows will be sent to villages in developing nations to provide an 
inexpensive alternative to mother’s milk. “Herman was engineered by Gen Pharm International 
of Mountain View, CA, and the calves were born following a breeding program established at 
Gen Pharm's European laboratory in Leiden, Netherlands” (Biotech Notes 1994). Studies done 
on the milk of the transgenic cattle show that the lactoferrin production is high enough to meet 
the needs of human children. “Hence, a few hundred animals could  
 
 
 
 
Figure 7: Herman and his offspring -- Gene 
Pharming, Netherlands produce first 
transgenic bull, 'Herman'. (Heaf, 2005). 
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supply thousands of kilograms of the product annually, and changes in dosage regimens, market 
projections, and additional applications of the pharmaceutical can easily be met by expansion of 
the herd” (Van Berkel et al, 2002). With improved methods of generating transgenic cows, and 
the ability to choose the gender of the transpharmer cattle, a herd of milk-producing cows can be 
efficiently made today. 
In addition to cows and sheep, transpharmer goats have been created. One advantage to 
using goats over cows is that goats are not susceptible to “mad cow” disease and yet still produce 
abundant milk. Two of the major companies involved in transhparmer goat creation are 
Genzyme Transgenics Corporation based in Massachusetts, and Nexia Biotechnologies based in 
Quebec, Canada. Genzyme is focusing on developing goat-pharmed medicines and tools for 
medical research, while Nexia is pursuing the more industrial applications of goat pharming 
(Gaffney 2003).  Genzyme Transgenics Corporation, in early 1999, announced in Nature the 
creation of a transpharmer goat named Grace. “The goat's milk tested positive for the human 
protein ATIII, a protein normally found in human plasma that helps regulate blood clotting” 
(GTC Biotherapeutics 1999).  Researchers hope to use the protein in a treatment for heart disease 
and stroke. “Pre-clinical trials proved successful and were approved by the FDA and clinical 
trials are now underway.  The market for ATIII is $200 million annually, and this amount of the 
transgenic protein can be produced by a herd of less than 100 goats, each initially costing a half 
to $1 million per doe” (Gaffney 2003).  While the goats may prove to be medically and 
pharmaceutically useful, they also have a strong potential for profit. 
On the industrial side of transpharmer goats, Nexia has engineered goats that might also 
provide a rich profit. “Nexia Biotechnologies' top pharm product is Biosteelä, genetically 
engineered spider silk proteins produced in goats’ milk.  It is three times stronger than Kevlarâ, 
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which is used to make bullet proof vests, and the strongest material on earth that can be woven 
into a fiber. It can withstand up to 600,000 lbs. per sq. in. pressure.” (Gaffney 2003). Using goats 
rather than spiders has many advantages, one of them being that the spiders cannot be 
domesticated as easily as goats and they tend to be defensive and violent. Nexia’s success with 
the spider silk proteins has already lead to research funds from the United States government to 
develop Protexiaä, a form of butyrylcholinesterase (BchE). This protein is known to protect 
against nerve agents, and while it is present in human blood, it is not in sufficient quantities to 
protect against nerve agent chemicals. A transgenic animal capable of the production of 
Protexiaä would be a big advantage to United States troops. 
The last group of Transpharmer animals includes transgenic rats, mice and some rabbits.  
The first Transpharmer animal produced was a mouse in 1987 that secreted sheep β-
lactoglobulin in their milk (Houdebine, 1997).  Mice are useful for transpharming because they 
are relatively cheap and reproduce swiftly. Not surprisingly, however, small animals such as 
mice prove difficult to milk, and the process is relatively time consuming and lacks efficiency. 
Nonetheless, they are suitable for use when only a small amount of protein is needed (Houdebine, 
1997). For example, when protein is needed for studying its biochemical properties, as in 
crystallization, the proteins can be produced by a mouse using recombinant and transgenic 
technology. The protein in the milk is in enough abundance that only a few milliliters often 
provides the milligrams needed for research (Houdebine 1997). Often the Transpharmer mice 
and rabbits are milked using a vacuum and oxytocin to stimulate the mammary gland to release 
milk, and the milk can be collected daily while the animal is lactating. For a rabbit, the amount 
of milk collected per nipple is between 10 and 20 ml (Houdebine, 1997), so although the animals 
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are small, the amount of protein they provide can merit production of recombinant proteins at a 
commercial level. 
 
Xenotransplanters 
Commercially and medically, a class of animals called Xenotransplanters has potential. 
Xenotransplanters are transgenic animals designed for the use of “the [transplantation] of animal 
cells, tissues and organs to treat or mitigate human diseases” (Carnell 2000).  The hope is that 
using animals to grow cells and organs for humans in need of transplants could eliminate many 
of the problems with today’s organ transplant process.  For example, an adequate supply of 
organs would reduce the waiting period which often outlasts the lives of the patients in need of 
the organs. Also, if the cells could be grown to be specific to the person in need of them, there 
would be less of a chance of rejection by the patient. Xenotransplants could affect the treatment 
of “diseases (such) as diabetes, end-stage renal disease, Parkinson's disease, acute and chronic 
liver failure, and inherited metabolic disorders” (Catez, 2005).   
However, many problems surround the use of Xenotransplanters mainly due to the fears 
that disease could be spread from the host animal to the human receiving the transplant. “Pig 
retroviruses can infect human cells, fueling concerns about the safety of xenotransplantation” 
(Pennisi and Normile, 2000).  Viruses that can be transmitted from animal cells to human cells 
pose a risk of spreading disease to already ill people, or even have it spread to the general 
population.  However, animals kept in a disease-free community and environment, and screened 
for known pathogens, can be kept safe from viruses, and could provide a source of much-needed 
human tissue. 
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The most commonly considered animal for xenotransplant is the pig. Pigs are the most 
physiologically similar animal to humans that is readily available for scientific and medical use 
(chimpanzees are expensive and very difficult to obtain). "The idea of using parts from pigs to 
save humans is not new. For years people have been routinely given pig heart valves when they 
receive heart valve transplants” (Catez, 2005).  However, there is a problem of rejection with 
organs and tissues transplanted from pigs to humans. “Among the problems encountered has 
been the issue of immune compatibility.  Pig cells carry a marker not found in humans, and the 
human immune system targets them for destruction” (Catez, 2005). The cell markers are a sugar 
that is seen as a foreign antigen and targeted by the immune system, which leads to rejection and 
organ failure. Researchers have been struggling to create a pig that does not carry the cell 
markers that lead to the immune response. “A team led by researchers at the University of 
Missouri, Columbia, has made another major advance--the creation of four cloned piglets that 
lack one copy of a gene that causes pig organs to be rejected by the human immune system” 
(Kaiser, 2002).  However, this success is limited; while it proves that progress is being made, the 
process is far from perfect. “Researchers managed to knock out one of the two alleles (gene 
copies) for this marker in pigs successfully, but attempts to knock out both alleles have not 
worked” (Catez, 2005). Until all the markers on pig cells which incite attack by the human 
immune system can be removed or mutated to be insignificant, there is a large risk that cells and 
tissues from pigs will not be accepted by the human body, thus causing transplants from pigs to 
be ineffective. 
Nevertheless, attempts have been made to transfer pig blood into diabetics to reduce their 
need for insulin injections; so far the results have been mixed. While one girl in Mexico no 
longer needs insulin injections, nearly half of the patients in a recent xenoplantation study on 
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diabetics did not improve. With other attempt at xenotransplantation, In 1995 an AIDS patient 
was given injections of baboon blood in the hopes that his condition would change, and while he 
is still alive today, he has not seen any improvement. With the lack of any great success, 
xenoplantation is not a viable option for patients today until the process is more refined. 
 
Transgenic Food Sources 
A fourth major class of transgenic animals is the group of animals that have been altered 
to be improved food sources. Animals such as fish, pigs, and cattle have been engineered to 
provide more food per animal, and also to be leaner and more efficient food sources. Often, the 
addition of growth hormones to the animal is used to increase size beyond that of the animal’s 
natural stature.  For example, with the creation of a pig later labeled “Superpig” for its large size 
after it was engineered with to produce oGH (ovine growth hormone), “the liver, kidney, adrenal, 
and thyroid weights were all significantly heavier for the oGH expressing transgenic pigs than 
for non-transgenic littermates. Total carcass fat, longissimus muscle fat, subcutaneous backfat 
thickness, and loin eye area were lower, and carcass protein and water content and bR fiber area 
of longissimus muscle were higher in the transgenic pigs with elevated oGH than in their 
littermate controls ( P < .05 for each)”  (Pursel 1997). The pig clearly had muscle growth that 
exceeded that of its non-transgenic littermates, and it also produced leaner meat. However, the 
animal’s large size led to a number of health problems, and the pig eventually had to be put 
down.  While it is considered a transgenic success, the animal could not ethically be used due to 
the suffering it endured. 
While “Superpig” turned out to be a disaster as far as the overall health of the animal, 
transgenic fish engineered to be larger than average were a success. Such fish are designed to be 
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larger, more adaptable to cold water, and more disease resistant, and in general better able to 
survive than natural fish in the wild. These so-called “superfish” can show up to 11 times larger 
weights than their non-engineered counterparts.  However, there has been more success in 
creating large transgenic animals out of non-domesticated fish, possibly because domestic fish 
already have been selected for larger growth, and it also appears to be dependent on whether the 
fish are a naturally fast-growing species, such as trout, as compared to slower-growing species 
like salmon. “The effect of introducing a growth-hormone gene construct into fish to increase 
growth rates appears to be dependent on the degree to which earlier enhancement has been 
achieved by traditional genetic selection” (Devlin et al, 2001).  While producing larger fish could 
reduce the strain on natural fish populations and make fish more available to the consumer, there 
are doubts as to whether it will be available for consumption soon. Many are concerned over the 
health effects of genetically engineered food upon humans, and concerns over this controversy 
have kept the transgenic fish from the consumer market and thus the dinner plate. There are also 
concerns about how these fish would affect natural ecosystems if released into the wild. These 
concerns keep most of transgenic animals from entering the average consumer’s diet to this day. 
 
Biological Models 
The final major category of transgenic animals includes the biological models. These 
transgenic animals are typically mice created to explain or elucidate various biological processes 
or biological mechanisms of development. The first notable biological model is “Supermouse”. 
Supermouse was engineered to be large in size based upon the insertion of growth hormone 
genes, similar to the study using Superpig. Scientists injected a rat growth hormone gene 
attached to the metallothionein gene promoter into fertilized mouse eggs and a number of the 
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resulting litter grew significantly larger than their non-transgenic littermates. “This approach has 
implications for studying the biological effects of growth hormone, as a way to accelerate animal 
growth, as a model for gigantism, as a means of correcting genetic disease, and as a method of 
farming valuable gene products” (Palimiter et al, 1982).  Supermouse was the first successful 
transgenic animal, and its creation opened up the large field of bioengineering animals. 
Another example, a rhesus monkey produced in 2001 and called ANDi, used a gene 
isolated from jellyfish and was the first successful transgenic primate. “The major obstacle in 
producing transgenic nonhuman primates has been the low efficiency of conventional gene 
transfer protocols.  By adapting a pseudotyped vector system, efficient at up to 100% in cattle, 
we circumvented problems in traditional gene transfer methodology to produce transgenic 
primates” (Chan et al, 2001).  
  
Figure 8: October 2 2000: Birth of first genetically modified primate, a rhesus monkey named ANDi (inserted 
DNA backwards) and containing a fluorescent marker gene from a jellyfish, at Oregon Regional Primate 
Research Centre, USA (news released on 12 January 2001). 224 eggs were injected with the gene. On 
fertilisation these yielded 40 viable embryos from which 5 pregnancies resulted. Of 3 monkeys born live, tests 
show that only ANDi carries the gene, although it is not being expressed. (Heaf, 2005) 
 
 
 31 
Researchers at the Oregon Regional Primate Research Center in Beaverton inserted the 
gene coding for green fluorescent protein (GFP) (Vogel 2001).  Although the monkey is not 
green unless viewed under fluorescent light, the principle of transgenics that ANDi illustrated is 
important. “For questions that are difficult to study in rodents, such as those related to aging, 
neurodegenerative diseases, immunology, and behavior, transgenic primates could prove a plus” 
(Vogel 2001). It proved that the process could be done, and that later attempts with transgenic 
primates could lead to greater developments in the understanding of human diseases and 
conditions. 
A third type of transgenic biological model is the so-called “Smart Mouse”, also known 
as Doogie. Announced in 1999, this mouse was transgenic with genes to alter learning ability 
and improve memory, and the results of behavior and memory tests were exciting. 
“Neurobiologist Joe Tsien, with collaborators at MIT and Washington University, found that 
adding a single gene to mice significantly boosted the animals’ ability to solve maze tasks, learn 
from objects and sounds in their environment, and to retain that knowledge. This strain of mice, 
named Doogie, also retained into adulthood certain brain features of juvenile mice, which, like 
young humans, are widely believed to be better than adults at grasping large amounts of new 
information” (Harmon 1999). This study provided enlightenment about how the brain works to 
store memories and the biological processes involved in creating associations in the brain, which 
could lead to advances in medicine and therapies for neurological and even psychological 
disorders. “NMDA-dependent modifications of synaptic efficacy represent the unifying 
mechanism underlying a variety of associative learning and memory. Our data further indicate 
that neural activities at the 10–100 Hz range in the forebrain may be crucial for coding and 
storage of learned information. In addition, the identification of NR2B as a molecular switch in 
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the memory process has indicated a potential new target for the treatment of learning and 
memory disorders” (Tang et al, 1999).  The results also added fuel to the debate that intelligence 
is, in some ways, genetic.  From this study came questions about how this information might 
lead to genetic alterations in people, even though it isn’t known if the gene that was altered in 
“Smart Mouse” would have the same effect when altered in a human. 
A final example of biological models is “Youth Mouse”. The mouse was designed to 
achieve a greater lifespan than that of a normal mouse by overproducing in many brain sites the 
urokinase-type plasminogen activator (uPA), a protease implicated in fibrinolysis and 
extracellular proteolysis. “In alpha MUPA mice, overproduction of uPA in brain sites controlling 
feeding leads to reduced food consumption that, in turn, results in retardation of growth and body 
weight and also in increased longevity” (Miskina and Masos, 1997). “Youth Mouse” might aid in 
answering many questions about longevity, lifespan, and life-long health in humans. 
Upon reviewing the many different transgenic animals, there are many opportunities to 
learn more about how living organisms function. A lot of doors are opened in the medical and 
scientific worlds with so many different applications of transgenic technology. Hopefully 
someday transgenic animals will provide answers for some of humanity’s greatest ailments and 
diseases, as well as provide a more efficient and healthy food supply to the growing human 
population. Transgenic animals, although not all successful, are worthy of attention and offer a 
great deal toward improving life in the future for people and animals alike. 
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Chapter 3: Transgenic Ethics 
 
 The genetic modification of animals by human beings has been going on for thousands of 
years. Farmers have long bred the best traits into their crops and their livestock to increase food 
and/or work productivity. However, the ability to directly modify genomes is a recent ability and 
many people still question humanity’s right to do so. Transgenic research has been under a lot of 
scrutiny over moral concerns regarding the ethics behind creating transgenic organisms. The 
benefits to humans of using animals for research include increased productivity, especially of 
food, a decrease in the need to use chemicals such as pesticides or herbicides, a reduction in the 
amount of animals used in testing products, and even the production of human medicines.  For 
example, “products such as insulin, growth hormone, and blood anti-clotting factors may soon be 
or have already been obtained from the milk of transgenic cows, sheep, or goats,” (Margawati, 
2003).  However, there are many factors which argue against the use of modified animals. 
 Factors which are considered risks to transgenic modification are often subjective. 
Depending upon a person’s individual beliefs and/or religion, altering an organism’s DNA may 
seem inherently wrong and even dangerous. There are a lot of unknowns in this relatively new 
science which have not yet been explored. People worry that transgenic science is moving too 
quickly to predict the consequences of our actions; perhaps we are overreaching ourselves when 
we alter things which we have never before been able to change. Also, the rapid development of 
technology and advances in the science of genetic modification lead to difficulties in stating a 
specific code of ethics.  As knowledge and capabilities in the field progress, the uses of and 
organisms created through transgenic technology affect different principles. 
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The ethics of transgenic animals is a complicated matter. The issue goes above and 
beyond that of basic animal treatment and care into the topic of the morality of using animals for 
the advancement of human interests. It is generally considered true that animals have interests in 
themselves beyond the instincts of survival, and would avoid pain and suffering at their choice. 
The balance between that pain and the advantages of human discoveries with the studies using 
live subjects is difficult to identify. Depending upon personal gain, benefit, or even a person’s 
upbringing, the balance between human and animal interests is weighed differently between 
individuals, and the lack of specific ethical guidelines can lead to a certain amount of strife 
between researchers and animal welfare parties. 
One of the first issues involving the use of animals in studies is that animals have an 
intrinsic value in themselves. There are many reasons a person may argue for the use of animals 
as research subjects, which can include the evolutionary status, cognitive ability, consciousness 
and expression, quality of life, and/or lifespan of the animal to be used for transgenic research (or 
any biological research, for that matter). Claims that animals are somehow lesser beings than 
humans are often used to explain their usage in labs. “They’re just mice,” or is often the attitude 
taken by advocates of animal research. However, once more intellectually complex organisms 
are involved (such as primates or even pigs) many people question that mentality.  No matter the 
type of creature, there is undoubtedly a value of the unaltered, natural state of an animal that 
cannot be ignored. Many question the right of man to “play God” by altering the state of being of 
animals, and some fear that the consequences will not only cause harm to the animal in question 
but in the end to the human race, whether by the moral degradation in mankind or through the 
creation of a dangerous organism. 
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Fear of the consequences is another argument made against the ethics of animal use in 
laboratories. Some fear that by altering things which were, until recently, out of our control, we 
might begin something destructive. There are questions as to whether we might create something 
out of our control, and in the end do more damage than help through the procedure. The welfare 
of modified animals is often in question. It would be a horrible thing to do a modification on an 
animal only to have it exist continuously in pain or suffering. For example, “What is life like for 
an oncomouse, who has been constructed to develop cancer, or of the USDA engineered 
‘Beltsville pig,’ who was ‘bowlegged, cross-eyed, arthritic, and barely able to stand up?’” 
(Hettinger, 1992). Quality of life after the animal has been altered is important and care must be 
taken to avoid making the animal live in a state worse than that of its natural state of being. 
Shortened life spans must be avoided as well. Also, there are concerns about the effects of 
modified organisms on the environment. An organism with an added advantage could in some 
cases destroy an ecosystem, or at least disrupt the natural balance of life in a food chain. 
Religion often clashes with biological modification. The right of humans to alter or 
meddle with living beings is denied by most religious tenets. “Playing God” by changing the 
fundamental makeup of other creatures causes unease and controversy among the religious.  Also, 
some religions hold certain animals to be sacred, such as Hindus and their veneration of cows. 
To the Hindu, a transpharmer cow would be sacrilegious. Even if the cow suffers no apparent 
harm by producing altered milk, it is still against the Hindu philosophy to create such a creature. 
There is a common opinion that God created things as they are for a purpose and that altering 
organisms from “the way they are supposed to be” is sinful or wrong. Many religions consider 
man’s meddling in genetics to be harmful since, according to religious doctrines, humans were 
not meant to have the power to create transgenic organisms. Islam, Hinduism, Judaism, 
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Buddhism, and even Christianity preach that all creatures should be treated with respect, 
compassion, and care, while some religions even suggest vegetarianism. On the flip side, 
religious views, especially with Christianity, are often that humans were given “dominion” over 
animals by God; humans have souls while animals do not. It has been said that since creatures 
have evolved on their own over time from the original ones put onto Earth by God, then perhaps 
it is God’s will that animals change, whether it be through natural means or aided by biotechnical 
technology.  
 However, when humans involve themselves in changing organisms, there is some feeling 
about there being an “unnatural” mixing of genes when transgenic modifications take place. For 
example, it is unsurprising to be uncomfortable at the thought of mixing plant an animal DNA to 
create a modified organism. Some opponents of genetic modification make the claim that even 
the mixing of insect and reptile DNA, for example, is wrong and that we humans are taking a 
risk. It is a fear that by adding such genes to an animal we are making it less of what is was; by 
altering its identity it loses its place in its species.  “Anxiety, distaste, or even revulsion, may be 
expressed about the 'unnatural' mixing of kinds - about creating chimeras, about altering the 
'telos' of species (so as to interfere with a pig's 'pig-ness', for example), about crossing the 
species barrier, and about the mixing of genes between humans and other animals” (The Boyd 
Group, 2005).  Whether these objections arise out of religious or philosophical beliefs, the 
feeling of transgenesis being “unnatural” causes many to balk at transgenic organisms or even 
products of transgenic research. 
 It has been suggested that transgenic animals could help ease the suffering of laboratory 
animals by creating animals that are not sentient but are otherwise the same creatures as are 
already being used in laboratory research. For example, if a rabbit were to be created that would 
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survive as a normal rabbit would, but would not have the capability to think or feel pain the way 
a normal rabbit would, it could relieve the suffering of normal laboratory rabbits in testing. Since 
the animal would supposedly not suffer when experiments were done upon it, it makes it perfect 
for performing experiments. However, the creation of such organisms is questionable. How 
would one know, in the end, that the animal is not suffering?  Also, if animals could be created in 
such a manner, what would stop someone from creating a human being that way and claiming 
that it is suitable for lab work because it has no mind or even soul to suffer?  While such a 
creature would undoubtedly be useful for research purposes, it really is neither practical nor 
ethical for many reasons. 
 Nonetheless, transgenic animals have been produced that do not suffer, at least according 
to any standard we can measure, 
and have provided a lot of 
scientific insight. One positive 
example of transgenic animal use 
is in transpharmer cows. These 
cows produce milk that contains a 
pharmaceutical benefit while they 
themselves do not suffer. The 
genetically altered cattle are a 
convenient and economical way to 
provide nutrients and favorable  
 
    Figure 9: The Monetary Value of Various Transgenic  
 Animals. (Betsch, 1995). 
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proteins while using fewer hormones to produce milk.  Rosie, a cow who made her first public 
appearance in 1997, was the first successful transgenic cow to produce modified milk. “Rosie 
and her fellow cows have produced the human proteins α-lactalbumin, an important nutritional 
protein rich in amino acids and particularly useful in feeding premature babies” (Edwards, 1997). 
Her milk is more nutritionally balanced than natural cow’s milk and may be more suitable to 
babies and elderly that have specific dietary needs. Since then, cows, goats, and sheep are being 
created to produce proteins to help phenylketonuria (PKU) and cystic fibrosis, as well as insulin, 
growth hormone, and blood anti-clotting factors. Human hemoglobin has been produced in 
swine’s blood. Unfortunately, the price of buying a transpharmer animal (see Figure 9) is one of 
the main deterrents toward their use today; production of a transgenic animal is costly and the 
successful animals produced that carry the desired trait are few.  Once these animals can be 
reliably and efficiently created, these farm animals will be a boon to undeveloped countries; 
raising a cow that produces a much-needed pharmaceutical component in its milk could be more 
economical and accessible than buying drugs (Margawati, 2003). Transpharmer cows do not 
suffer but have large advantages to human welfare. 
Another example of a successful transgenic animal is that has little to no suffering is the 
Alzheimer’s Mouse (also known as Athena Mouse), which was developed to aid research in the 
development a vaccine for Alzheimer’s.  Created in part at WPI in collaboration with the former 
Transgenic Sciences Inc, then sold to Athena, this transgenic animal uses a gene which has been 
shown to cause early onset Alzheimer’s disease in some families to develop symptoms similar to 
Alzheimer’s, and the mouse’s creation has lead to greater understanding of the disease. Having 
an animal model for the disease in which the animal successfully showed the pathology of 
Alzheimer’s has lead to many discoveries and developments in the treatment and comprehension 
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of Alzheimer’s that might be applied to human Alzheimer’s patients. Although several 
improvements on the animal have been made since its initial development was announced in 
1995, the advantages to using transgenic animals in research were clearly shown with the 
creation of the original mouse.  And the animal does not suffer by any criterion that can be used 
to measure suffering in animals. 
 Some mouse models for human disease are not as successful, however. One of these 
examples is the Oncomouse, also known as Harvard Mouse. Oncomouse has been given 
oncogenes that create higher susceptibility toward cancer development, as well as to be more 
sensitive to carcinogenic substances. These genes have allowed scientists to explore the 
environmental, as well as the genetic, causes of cancer. While the animal has provided many 
insights into cancer and cancer treatment, there is a possibility that the animal suffers from the 
disease it has been created to develop. “ ‘Oncomice develop tumours in a variety of places 
including mammary tissue, blood, skeletal muscle, the lungs, the neck and the groin. Tumours 
can lead to severe weight loss (40% body weight or more) while large tumours may ulcerate. In 
some instances, oncomice have suffered limb deformities as a side effect of the genetic 
manipulation.’ Half of the female oncomice develop breast cancer before they are a year old,” 
(Lyons, 2005).  To many people, these deformities and tumors are unacceptable. On top of the 
moral and ethical debates, the mouse, created through laboratories in Harvard University and its 
corporate partner DuPont, has been the subject of many patent struggles in countries across 
Europe and in Canada.  Although in 1988 it was the first animal to receive a patent from the 
United States Patent and Trademark Office (Shorett, 2004), many countries, including Canada, 
refuse to patent the mouse. The legal battles as well as the moral issues have made Oncomouse a 
greatly disputed issue.  
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Some of the most negative results from transgenic animals came from the creation of the 
Beltsville pig. Nicknamed “Superpig” for its enormous size (see figure 10), the pig was given a 
gene for a  
 
 
 
 
Figure 10: 1989 Publication 
(Science 254: 1281-1288) of data 
about the 'Beltsville pig', a 
transgenic pig (named after the 
agricultural research station in 
Maryland USA) which suffered a 
range of pathological conditions 
because it had a gene for human 
growth hormone. (Heaf, 2005) 
 
 
 
human growth hormone in order to create a larger pig with leaner meat. However, the side 
effects were disastrous. The pig was deformed and suffered a number of maladies, and in the end 
it could not support its own weight. The animal eventually had to be destroyed, and it has served 
as an example for critics of transgenic animal research. Since its creation, the development of 
“super” animals has been halted. 
Other studies using transgenic animals have had poor results as well. “In gene deletion 
experiments, frequent multiple pathologies have been observed, including deformed genitals, 
missing limbs, extra limbs, involuntary movements, and gross deformities of the head and brain” 
(Lyons, 2005). Scientists must be careful to avoid creating more problems and defects than are 
ethical with which to subject an animal, in the name of progress. Also, time and care must be 
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taken to avoid mistakes that, in the end, cost more animal lives than is necessary. An animal that 
is suffering does no good toward solving problems; it only creates them. 
Another concern is that breeding (or crosspollination from plants) between modified 
organisms and natural organisms will occur. Questions arise over the spread of altered genes and 
its effects upon the environment. If a transgenic creature is prolific and has an advantage over the 
natural form of the species it could potentially cause a major disruption in the survival of the 
natural organism. Also, the effects of those creatures upon other creatures are unknown; for 
example, a plant carrying modified recombinant DNA might survive well, but the animals 
feeding upon it may suffer ill effects (GHS Biotechnology, 2005).  Also, breeding between 
natural species and modified species could also create differences in the organism which could 
potentially be harmful to other species that depend upon it for survival. Also, the fear that 
evolution of these new genes will lead to stronger and better adapted pests, such as bugs or 
bacteria, is strong. If the addition of a gene leads to a resistant strain of bacteria which could 
cause illness to humans or animals, it would be a disaster. Fears such as these drive opponents of 
transgenic organism technology. 
There is also a lot of concern and public tension over the introduction of genetically 
modified material to food; it is this apprehension which has lead to the explosion of “organic” 
foods on sold on the market today. People worry that genetically altered plants, animals, or 
products and derivatives from modified plants and animals, will cause harm. These so called 
Franken Foods are very common due to the advantages of genetic engineering in producing 
faster-growing and more productive crops and livestock, and some consumers even go so far as 
to ensure that their cows are not only transgenic, but that the feed given to the cows was 
unaltered as well. Although most of the transgenics in farm products has been focused upon 
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improving plants, “transgenic farm animals (TFAs) have also been ‘genefactured’: cattle, 
chickens, pigs,  rabbits, sheep fish, and goats. The ‘geep,’ an animal with the body of a sheep and 
the head of a goat (see Figure 11) produced at the University of Wyoming, has probably attracted 
the most public attention,” (Comstock, 2003). Cows have been engineered that are resistant to 
bovine spongiform encephalopathy  (BSE), more commonly known as mad cow disease, and 
cows are also being developed that have more productive and pathogen free milk. These animals 
could be very beneficial to society; however, 
many people still do not feel comfortable 
consuming products that have been 
genetically modified. 
Nonetheless, the global demand for 
food is growing, and genetically modified 
food sources appear to be a reasonable 
solution toward meeting that need. 
Organisms that are resistant to disease, grow quickly, 
and produce more food products have great potential in 
reducing global hunger. Also, the genes added to crops could produce foods that are more 
nutrient rich, containing desirable vitamins that natural plant produce would not.  
Although the advantages to food genetically fortified with vitamins, disease resistance, 
and other rewards seem many, there is still a lot of resistance to the spread of transgenics as a 
solution. While some people might argue that more crops could be planted instead of using 
modified organisms, “an increase in crop yield is more likely to be pursued than an increase in 
land use, as clearing land is costly and also results in the loss of biological diversity” 
Figure 11: The “Geep” (Heaf, 2005). 
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(Environmental News Service, 2000). The positive effects of using modified organisms, with 
plants especially appear to outweigh the dangers. For example, foods which naturally are 
harmful or easily destroyed, such as a breed of rice that causes sterile offspring or a fruit tree that 
is easily destroyed by virus, can be altered to prevent these problems (Environmental News 
Service, 2000).  Nonetheless, there are other alternatives for supplying adequate food that are 
more acceptable to many, such as agreocology. Agreocology uses the mixing of crops to protect 
against predators and produce larger yields at harvest, and using agreocology would keep local 
farmers from relying upon organisms supplied and patented by limited sources or governments, 
which is a risk with the use of transgenic organisms. On the other hand, those natural crops do 
not have the nutritional or survival advantages that an engineered organism might have.  
Finally, ethics and legal issues often collide, as seen with the Oncomouse. A major issue 
with transgenic technology is the rights of patenting the organism or technology. While it is 
understandable that the research group and its investors should have a right to their discoveries 
and a right to protect their product, there is concern that the patenting of specific organisms will 
limit availability and further research. Limiting an invention with the possibilities to improve life 
for many to the hands of a few could be an unjust impediment toward more discoveries. “It is 
wasteful and inefficient… for society to let only one person (or institution) use and benefit from 
something that all could use and benefit from concurrently” (Hettinger, 1992).  After all, 
increased access to a transgenic animal could contribute toward research in other laboratories 
than only the few which have rights to it through the patent.  With more availability for 
laboratories to use the animal for research, more useful discoveries could be made. However, 
obtaining excusive rights to such an important creation as a transgenic animal is lucrative, and 
without the option to patent, investors may not be willing to invest time and money into 
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transgenic animal research. Obtaining a patent is incentive for the animals to be created in the 
first place. One solution to such a problem would be to provide public funding for research and 
to allow free use of the discoveries. However, until that happens, the private investor will desire 
exclusivity on their inventions. 
In addition to the financial aspect of patenting, there is a sense of natural entitlement for 
the creator to have a right to the creation. The question of patent rights often boils down to the 
simple issue of the definition of property. “This originally Lockean argument boils down to the 
intuition: I made it and hence it is mine; it would not have existed but for me” (Hettinger, 1992). 
However, many question that organisms, especially animals, should be considered intellectual 
property. While an inventor of a nonliving product may feel entitled to his creation, it is disputed 
whether or not a scientist working with living things can completely assume ownership.  It is a 
common opinion that “If anything is naturally entitled (that is, entitled by nature) to own a living 
organism, it is that living organism itself” (Hettinger, 1992). When considering the origins of 
property and the entitlement to property, it is assumed that a person’s body and the use of his or 
her body is naturally a personal right. Why should it be any different for the bodies of animals? 
For example, a rabbit is born with its own DNA, and that rabbit’s DNA does not purely belong to 
the scientist who uses it. The animal has some ownership and rights toward its use. Many assume 
that animals, with their own rights and value, should be the proper owners of their bodies, and 
this argument counters that of patenting transgenics.  
Nonetheless, the needs of humans often outweigh the ownership specific to an organism, 
and human ideas of property can offset the intrinsic property rights of a modified animal or plant.  
Also, the argument can be made that the modified animals have capabilities or aspects that are 
not natural; they are not the property of the animal and thus can be patented. While it is not 
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justifiable to assume that since an organism has been genetically altered and can serve a human 
purpose it no longer has any rights of its own, it is difficult to declare that the organism has the 
same ownership to itself that a natural animal or plant of the same species would have. 
Ownership issues aside, the basic rules of transgenic research should be the same as those 
that govern medical doctors: (if possible) do no harm. While some problems will develop as 
unexpected results occur while developing transgenic animals and technology, any pain or 
suffering on the part of the modified organism should be avoided. If unexpected suffering arises, 
it is imperative not continue that line of animals.  Everyone can agree that it serves no purpose to 
create a creature that is always in pain. However, the needs of animals and their basic welfare 
must also be balanced with the needs of people and the potential discoveries to which a 
transgenic animal might lead. Maintaining and reaching that balance will the effort of many 
people and the cooperation of many interests. 
The many moral issues surrounding transgenic animals will not be decided quickly or 
settled easily. Improved technology and greater public education on transgenic research is 
needed to solidify a specific code of ethics. The more people understand about the process and 
the results of genetic alterations in organisms, the more likely it will be that people can agree on 
what should and should not be done. Also, proper management of the technology needs to be 
decided. Many of the legal problems that exist today with creating and using transgenic animals, 
such as patent rights, will have to be resolved. The rights of the animal will need to be preserved 
and balanced with the usefulness of transgenic organisms.  Nevertheless, the ethical issues 
surrounding transgenic modified animals are very complex and often subjective, and some 
arguments may never be completely solved. 
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Chapter 4: Transgenic Legalities 
 
 One of the major controversial topics surrounding transgenic animals is whether or not 
they should be patented.  Since the law is generally chronologically behind the fast moving 
technological world, it was no surprise that there was no law that focused on the patentability of 
transgenic animals when the first transgenic animal was created.  There have been many cases in 
which scientists have pleaded their standpoint in the courts to claim that they should be able to 
patent their animals and reap the monetary benefits, and they have met just as much resistance 
from animal rights groups claiming that life should be held sacred and no financial value can be 
placed on it.  Especially in the case of oncomouse there were many appeals to this court case 
which has now become a cornerstone in transgenic legalities. 
 
US and European Oncomouse Cases and Appeals 
 The US Patent and Trademark Office receives thousands of patent requests per year on 
every kind of invention imaginable.  A patent is a grant made by a government that gives the 
creator of an invention the sole right to make, use, and sell that invention for a period of time.  In 
the United States, the length of a patent is generally 20 years.  During those 20 years the inventor 
is able to collect money on just about everything that has to do with their new invention.  They 
can profit by selling, mortgaging, using, or licensing their technology to others to make further 
advances in their field. 
 The first time that the US Patent and Trademark Office (PTO) had to decide if transgenic 
animals could be patented was in 1984 (Marshall, 2002).  A scientist at Harvard University 
named Philip Leder filed his application to patent the cancer-prone mouse which he called 
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oncomouse.  He produced this mouse by inserting oncogenes, which cause the proliferation of 
mammalian epithelial cells when they are activated, into the mouse’s genome.  Following the 
insertion, the oncomice would develop cancer, and Leder and his colleagues could use the mice 
to study the progression of these tumors. 
 The PTO granted this patent application as well as two other applications that Leder and 
his colleagues had.  They have patent rights for oncomouse itself (Leder and Stewart, 1984, 
patent # 4,736,866), for the method of  providing a cell culture from a transgenic non-human 
mammal (Leder and Stewart, 1992, patent # 5,087,571), and for the testing method using 
transgenic mice expressing an oncogene (Leder and Stewart, 1999, patent # 5,925,803).  The 
grant of the ability to patent life caused severe outrage from many animal rights organizations 
and for religious groups.  They would spend the next few years in court to question the authority 
of the PTO to grant a patent on life.   
  One appeal in the US reached the Court of Appeals for the Federal Circuit, and the ruling 
was that the plantiff, the Animal League Defense Fund, did not have the standing to challenge 
the PTO’s authority to grant animal patents.  The creators of oncomouse did not stop there.  They 
also applied for a patent from the European Patent Office (EPO), and the first time around they 
were denied the patent rights.  They appealed the decision and on the first try the EPO granted 
the patent for oncomouse.  It became European patent no. 0,169,672.  This ruling provides two 
very important conclusions.  The first is while Article 53(b) states that animals are excluded from 
patentability, Article 52(1) states that patents are available for all inventions capable for 
industrial application and therefore under Article 52(1) a transgenic animal can be seen as 
capable for industrial application (Sharples and Curley, 2005).  The second conclusion can be 
drawn from Article 53(b) which includes the phrase “animal varieties” rather than animals, or 
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animals as such, meaning that animals were not completely excluded from patentability under 
this article of the European Patent Convention. 
 Another important point that came out of this appeal was that the Technical Board of 
Appeals weighed the suffering of the animal against the benefits of the research to mankind.  
Ultimately they decided that the benefits of oncomouse to mankind outweighed the risks that 
were associated with the technology for creating and maintaining these special mice, and thus the 
EPO overturned the previous decision to allow the patent for oncomouse to Leder and his 
colleagues at Harvard University. 
 
Canada Denies Oncomouse Patent 
 Once again Leder and his colleagues filled out an application for a patent, but this time 
the patent was filed in Canada.  Initially the patent was denied in Canada because the creation of 
the mouse did not meet the Canadian patent law’s requirements of “manufacturing” or 
“Composition of matter” (Check, 2002).  Furthermore, the commissioner of patents decided that 
“a complex life form does not fit within the current parameters of the Patent Act without 
stretching their meaning of the words to the breaking point” (Mitchell and Somerville, 2002). 
Leder and his colleagues were not dismayed by this decision because they had received it before 
from the European Patent Office.  They simply appealed the decision.   
The appeal was heard by the Federal Court of Appeals, and they decided that oncomouse 
did in fact meet the requirement of the Patent Act under the heading “composition of matter.”  
They did not agree with the commissioner’s finding that higher life forms should not be patented.  
The justices also referred to a case that allowed the patenting of a microorganism because if the 
microorganism was permitted for patenting, they believed that oncomouse should be patentable 
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as well.  This court had decided that if an invention came about by human intervention then the 
invention can be patented so long as it is not obvious based on prior art. 
Quite obviously the animal rights activists and religious groups were very unhappy with 
this decision.  They decided to act on this outrage so the Government of Canada filed an 
application to appeal the oncomouse decision to the Supreme Court of Canada.  They argued 
their case that “granting patents on animals would be indicative of a morally problematic shift in 
humans’ perception of the natural world” (Mitchell and Somerville, 2002).  They also argued 
that the patenting of animals would create barriers preventing the free and rapid dissemination of 
scientific research materials which is, in turn, affecting the research and discovery of drugs, and 
treatments (Check, 2002). 
 On December 5, 2005 the Canadain Supreme Court announced its decision regarding the 
oncomouse patent.  They decided in a close vote of 5 to 4 that the patent no longer was valid. 
The justices believed that the life of an animal could not simply be reduced to a “composition of 
matter” within the context of the Canadian Patent Act.  However it is important to understand 
that the decision was reached solely upon the interpretation of the Canadian Patent Act.  They 
did not make their decision based on the ethics surrounding the situation.  Mr. Justice Bastarache 
has said that even though their decision was based on the interpretation of the Canadian Patent 
Act “the patentability of…life forms is a highly contentious matter that raises a number of 
extremely complex issues” (Mitchell and Somerville, 2002). 
 
Benefits of Transgenic Patents 
 There are many benefits that could come from the patenting of transgenic animals.  First 
of all, it creates competition between scientists.  Competition is good because it promotes the 
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study of the field.  If more and more scientists are studying transgenic technology, more 
advances will be seen in a shorter period of time.  An example of competition working to its full 
advantage was the study of DNA.  Everyone was rushing to discover the structure of the DNA 
molecule because to researchers DNA was enigmatic molecule.  The discovery of the structure 
of DNA was pressed on by the researchers who wanted to become famous and well known 
through out the scientific community.  With transgenic animals, scientists can propel research by 
creating new methods that are more efficient for creating such animals.  Not only will the field of 
transgenesis benefit from this propulsion, other fields that use transgenic animals could benefit as 
well because there will be more transgenic animals to perform experiments on for the purposes 
of medicine and other such uses. 
 
  Figure 12: Taconic is another company that has been creating 
  transgenic animals to be patented.  This is one of the  
  company logos that are used (Borderline Hypertensive hybrid 
rats, 2005). 
  
Another benefit of the patenting of transgenic animals is they could potentially bring 
more money for biotechnological research.  If the animals prove to be lucrative, more and more 
companies will give money to research so that they can directly benefit from any patents that 
could be issued.  This benefits biotechnology because there is more money available for research, 
and as any biologist knows, the necessary lab equipment is not cheap.  The biotechnology 
industry is already one of the biggest industries in the US, therefore, if this industry becomes 
more and more successful, then the economy as a whole will profit. 
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Downfalls of Transgenic Patents 
 There are many potential benefits of patenting transgenic animals; however, there are 
some downfalls.  One major problem that the patenting of transgenic animals could present is 
hindering research.  If the patented animal is expensive or not readily available to the scientific 
community, research could be hindered because the funds for research grants are limited and 
most experiments are time sensitive so they need the animal right away for testing.   The patents 
could “bog down the testing of new therapies” because, in the case of oncomouse, the scientists 
at Harvard require that anyone looking to use this mouse must obtain a license to do so (Marshall, 
2002).  This could be burdensome to some companies, so the result is loss of research for new 
therapies. 
 Another potential downfall of patenting animals is their case precedents could be used to 
obtain patents on other “objects” that were not considered patentable before.  This could open the 
door to the patenting of humans.  Once a precedent is set, people will use that to open the door to 
other possibilities because it is essentially, in itself, a foot in the door.  Some scientists could 
look at this case as an opportunity to patent humans.  The US Patent and Trademark Office has 
laws that restrict the patenting of humans because they can not be considered property.  However, 
humans and animals are biochemically very similar.  The human oncogene was inside 
oncomouse, and the patent was still allowed.  Organs are inside humans, and genetic engineering 
could be performed on them.  The oncomouse patent case could be a way in for the scientists 
who think this way.   
 Once the oncomouse patent was granted in the US and EU, many more scientists have 
rushed to have their ideas patented.  This is a problem because people are just throwing ideas at 
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the PTO and hoping for the best.  The more non-sense patent applications the PTO gets, the more 
they are inclined to deny these patents.  After the patent of oncomouse was granted, more than 
300 groups flooded the patent office with their requests for patents on their animals that they had 
created.  So far both the European Patent Office and the US Patent and Trademark Office have 
only granted a few patents between them. 
 Also, when the PTO granted the patent of oncomouse, they granted the patent for 
oncomouse itself, its offspring and subsequent generations.  This poses a problem for any cancer 
research lab because they can not use the strain of mouse to just create their own mice because 
the transgenic technology is patented as well.  They must either buy mice that Dupont has 
created, or they can pay to create and breed their own mice, which does not have a 100 percent 
success rate.  This creates a financial strain that labs are already under, and Dupont is making 
their problem bigger.  In addition, these patents could stifle the research because most scientists 
feed off of other scientists ideas, and this is encouraged in the scientific community because not 
only are they looking for recognition of themselves, but they are looking for cures to diseases 
and other problems of mankind; therefore, there is an understanding among scientists that they 
share their work to promote faster discoveries.  The patenting of animals is encouraging the 
mentality that everyone is out for themselves, and this could lead to the slowing down of 
discoveries of treatments.   
 
Groups Against the Patenting of Animals 
 Since the oncomouse patent was granted in the US and Europe, there has been an outcry 
from the animal rights activists calling for the repeal of these patents.  These groups believe that 
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the patenting of life should not be allowed, and they are asking if animals are patented now, how 
much longer it will take until scientists are asking for a patent for a human-being. 
 One of these groups is the American Anti-Vivisection Society or the AAVS.  They are a 
non-profit organization who is fighting to end experimentation on animals in research.  They are 
also fighting to end cruelty to animals.  They have also filed legal action to challenge the patent 
on live beagle dogs (American Anti-Vivisection Society, 2005). 
  
 
 
 
 
 
 
   Figure 13: An ad that the AAVS 
   has created to stop the use of  
   animals in  research experiments  
(American Anti-Vivisection  
Society, 2005). 
 
Another group that opposes the patenting of animals is the Greenpeace Organization.  
The Greenpeace organization is an independently funded organization that works to protect the 
environment.  They are very much against genetic engineering in all of its forms, and are trying 
to increase public awareness of genetically engineered foods and animals (Greenpeace, 2005). 
The Animal Liberation Front (ALF) is another organization that is adamantly opposed to 
the patenting of animals.  They are an underground group of fanatics who want to reduce animal 
suffering in the world.  They are actively involved in violent acts such as the torching of research 
labs (Animal Liberation Front, 2005) 
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Figure 14: The ALF members protesting outside 
of a lab in New Zealand (Animal Liberation Front, 
2005).   
 
 
 
 
 
 The Canadian Environmental Law Association (CELA) is a non-profit 
organization that was founded in 1970, and is committed to use existing laws to protect the 
environment and advocate environmental law reform.  They also offer free legal advisory clinics 
to the public, as well as represent citizens’ groups who are unable to afford their own legal 
counsel.  The CELA was allowed by the Federal Court of Appeals in Canada to intervene in the 
case to deal with the public interest perspective regarding the interpretation of the Patent Act.  
Specifically their intervention dealt with the welfare of animals and the cheapening of respect for 
life (Canadian Environmental Law Association, 2005). 
The last animal activist group who is against animal patenting that will be discussed in 
this paper is the People for the Ethical Treatment of Animals (PETA).  The PETA is an 
international group that was founded in 1980.  Their mission is to establish and protect the rights 
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of all animals.  They are the largest animal rights organization in the world and they work 
through public education, research, animal rescue, legislation and many other means.    
 
 
Figure 15: Protestors of the PETA 
protesting the running of the bulls in 
Spain.  They claim it is cruelty to 
animals and thus should be stopped 
(People for the Ethical Treatment of 
Animals, 2005) 
 
 
 
 
 
 
 
 
 
IQP Opinion of Animal Patenting 
 The authors of this IQP believe that transgenic animals should be patented.  Scientists 
should be rewarded for their hard work and contributions to the scientific field.  Patenting of 
animals is good; however ethics should be strictly followed, with very strong legal mandates to 
care for the animals to minimize suffering, and a patent should not be awarded to scientists who 
performed experiments that were cruel to animals in any way.   
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Conclusion 
 
Many of the issues regarding transgenic animals have been explored in this IQP.  
Transgenic animals are animals whose genomes have been altered by the inclusion of foreign 
genetic material.  In chapter 1, a brief overview of the transgenic technological history was 
included in order to show the huge strides that transgenesis has made over the last few decades.  
Chapter 1 also includes the methods currently used for introducing a foreign piece of DNA into 
the genome of the desired animal.  Presently scientists are looking into other methods for 
creating these animals because the methods used right now are highly inefficient. 
The many types of transgenic animals include disease models, transpharmers, 
xenotransplanters, scientific models, and animals used as food sources.  From what research has 
so far been accomplished, the most useful of those appear to be the disease and scientific models. 
Disease models such as Alzheimer’s mouse have lead to many answers to current medical 
quandaries which would otherwise remain unknown, and have provided the necessary models for 
developing vaccines. While the other types of transgenic animals have great potential for human 
benefit, changes in and acceptance by society will most likely need to occur before they become 
mainstream. As has been described, there are still many concerns over genetically altered food 
sources as well as tissue transplant from transgenic animals. Hopefully, in the years to come, 
studies over the safety of using transgenic animals will succeed in convincing the public of their 
usefulness in today’s society. 
 Ethically speaking, society still has many doubts over the creation and use of transgenic 
animals. It is understandable to question the right of humankind to alter or change an animal’s 
basic form, and consequences of our tampering with genetics may yet prove to be negative; 
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however, with the results of transgenic research today, it is hard to deny the need for transgenic 
animals. While it may not be in the best interest of the animal in question, transgenic research 
has provided many important medical and scientific discoveries which may lead to a number of 
benefits for today’s society. The opportunities for advancement provided by transgenic research 
cannot be ignored. With the proper legislative precautions, ample care, and concern over basic 
animal welfare, it can be concluded that the overall good offered by transgenic animals more 
than balances out ethical questions against their use. 
Finally, since transgenic animals are fairly new, it was not surprising that there were no 
legal precedents that could help the courts in deciding if these animals should be patented.  
Patents are very important to scientists because they serve as compensation for all the time and 
money that they put into their discovery or invention.  The Harvard oncomouse served as the 
first animal that was ever patented.  The United States was the first to allow the patent.  In 
Europe the first request was denied, but this decision was overturned with the first appeal.  
Canada did not agree with Europe or the United States, and three years ago they denied the 
patent in their Supreme Court.  Since the patents were granted in the US and Europe, animal 
rights groups have been trying to appeal the decisions because they feel that life should be in 
higher regard.  Even though animal rights activists are adamantly opposed to the patenting of 
animals, the authors of this IQP feel that the benefits of patenting animals far outweigh the 
downfalls, especially with strong oversights in place. 
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